SK176197A3 - A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate - Google Patents

A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate Download PDF

Info

Publication number: SK176197A3
Authority: SK; Slovakia
Prior art keywords: vaccine; carrier; polysaccharide; conjugate; protein
Prior art date: 1995-06-23

Application number

SK1761-97A

Other languages

English (en)

Slovak (sk)

Inventor

Julien Peetermans

Pierre Hauser

Original Assignee

Smithkline Beecham Biolog

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-23

Filing date

1996-06-19

Publication date

1998-07-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451299&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK176197(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-06-23 Priority claimed from GBGB9512827.8A external-priority patent/GB9512827D0/en

1995-07-01 Priority claimed from GBGB9513443.3A external-priority patent/GB9513443D0/en

1995-12-15 Priority claimed from GBGB9525657.4A external-priority patent/GB9525657D0/en

1996-03-22 Priority claimed from GBGB9606032.2A external-priority patent/GB9606032D0/en

1996-06-19 Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog

1998-07-08 Publication of SK176197A3 publication Critical patent/SK176197A3/sk

Links

229960005486 vaccine Drugs 0.000 title claims abstract description 45
239000000427 antigen Substances 0.000 title claims abstract description 22
102000036639 antigens Human genes 0.000 title claims abstract description 22
108091007433 antigens Proteins 0.000 title claims abstract description 22
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 title claims abstract description 16
239000000203 mixture Substances 0.000 title claims abstract description 13
150000004676 glycans Chemical class 0.000 title claims description 33
229920001282 polysaccharide Polymers 0.000 title claims description 33
239000005017 polysaccharide Substances 0.000 title claims description 33
229910000147 aluminium phosphate Inorganic materials 0.000 title abstract description 3
229940001007 aluminium phosphate Drugs 0.000 title abstract 2
241000606768 Haemophilus influenzae Species 0.000 claims abstract description 13
208000015181 infectious disease Diseases 0.000 claims abstract description 6
238000004519 manufacturing process Methods 0.000 claims abstract description 5
239000003814 drug Substances 0.000 claims abstract description 3
102000004169 proteins and genes Human genes 0.000 claims description 11
108090000623 proteins and genes Proteins 0.000 claims description 11
229960000814 tetanus toxoid Drugs 0.000 claims description 11
229940001442 combination vaccine Drugs 0.000 claims description 10
206010013023 diphtheria Diseases 0.000 claims description 10
238000000034 method Methods 0.000 claims description 10
206010043376 Tetanus Diseases 0.000 claims description 9
229940047650 haemophilus influenzae Drugs 0.000 claims description 9
102000014914 Carrier Proteins Human genes 0.000 claims description 6
108010078791 Carrier Proteins Proteins 0.000 claims description 6
201000005702 Pertussis Diseases 0.000 claims description 6
238000002347 injection Methods 0.000 claims description 6
239000007924 injection Substances 0.000 claims description 6
241000709721 Hepatovirus A Species 0.000 claims description 5
208000002672 hepatitis B Diseases 0.000 claims description 5
238000001179 sorption measurement Methods 0.000 claims description 5
208000000474 Poliomyelitis Diseases 0.000 claims description 4
238000002156 mixing Methods 0.000 claims description 4
101710116435 Outer membrane protein Proteins 0.000 claims description 3
241000700605 Viruses Species 0.000 claims description 3
108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims 1
230000001268 conjugating effect Effects 0.000 claims 1
244000052769 pathogen Species 0.000 claims 1
230000001717 pathogenic effect Effects 0.000 claims 1
238000009472 formulation Methods 0.000 abstract description 5
229940045808 haemophilus influenzae type b Drugs 0.000 abstract description 4
201000010099 disease Diseases 0.000 abstract description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
229940031348 multivalent vaccine Drugs 0.000 abstract description 2
230000002265 prevention Effects 0.000 abstract description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
238000010168 coupling process Methods 0.000 description 7
238000005859 coupling reaction Methods 0.000 description 7
241000700159 Rattus Species 0.000 description 6
230000008878 coupling Effects 0.000 description 6
239000000047 product Substances 0.000 description 6
229960004443 hemophilus influenzae b vaccines Drugs 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
229910017119 AlPO Inorganic materials 0.000 description 4
229960000074 biopharmaceutical Drugs 0.000 description 4
229940124736 hepatitis-B vaccine Drugs 0.000 description 4
230000005847 immunogenicity Effects 0.000 description 4
229940029583 inactivated polio vaccine Drugs 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
230000021615 conjugation Effects 0.000 description 3
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
230000000694 effects Effects 0.000 description 3
230000003053 immunization Effects 0.000 description 3
238000002649 immunization Methods 0.000 description 3
230000004224 protection Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 2
-1 1-cyano-4-dimethylamino pyridinium tetrafluoroborate Chemical compound 0.000 description 2
ALEBYBVYXQTORU-UHFFFAOYSA-N 6-hydrazinyl-6-oxohexanoic acid Chemical compound NNC(=O)CCCCC(O)=O ALEBYBVYXQTORU-UHFFFAOYSA-N 0.000 description 2
241000588832 Bordetella pertussis Species 0.000 description 2
108010060123 Conjugate Vaccines Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
229940124914 Havrix Drugs 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
241000588650 Neisseria meningitidis Species 0.000 description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
150000001718 carbodiimides Chemical class 0.000 description 2
229940031670 conjugate vaccine Drugs 0.000 description 2
239000004643 cyanate ester Substances 0.000 description 2
230000007423 decrease Effects 0.000 description 2
229960003983 diphtheria toxoid Drugs 0.000 description 2
208000005252 hepatitis A Diseases 0.000 description 2
230000036039 immunity Effects 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
229940124884 Engerix-B Drugs 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229940124915 Infanrix Drugs 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229940124909 PedvaxHIB Drugs 0.000 description 1
JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
101710137302 Surface antigen S Proteins 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
229940031567 attenuated vaccine Drugs 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229940028617 conventional vaccine Drugs 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000011026 diafiltration Methods 0.000 description 1
229960005097 diphtheria vaccines Drugs 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
230000036541 health Effects 0.000 description 1
SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 1
SYECJBOWSGTPLU-UHFFFAOYSA-N hexane-1,1-diamine Chemical compound CCCCCC(N)N SYECJBOWSGTPLU-UHFFFAOYSA-N 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000002480 immunoprotective effect Effects 0.000 description 1
229940038490 inactivated hepatitis a vaccine Drugs 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000012263 liquid product Substances 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
239000012528 membrane Substances 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000008520 organization Effects 0.000 description 1
229940066827 pertussis vaccine Drugs 0.000 description 1
229960005323 phenoxyethanol Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000011176 pooling Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000008569 process Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000006722 reduction reaction Methods 0.000 description 1
238000006268 reductive amination reaction Methods 0.000 description 1
238000012770 revaccination Methods 0.000 description 1
HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000002904 solvent Substances 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
230000003319 supportive effect Effects 0.000 description 1
229960002766 tetanus vaccines Drugs 0.000 description 1
150000003568 thioethers Chemical class 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
238000002255 vaccination Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
Mycology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Immunology (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Pulmonology (AREA)
Gastroenterology & Hepatology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SK1761-97A 1995-06-23 1996-06-19 A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate SK176197A3 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
GBGB9512827.8A GB9512827D0 (en)	1995-06-23	1995-06-23	Vaccines
GBGB9513443.3A GB9513443D0 (en)	1995-07-01	1995-07-01	Vaccines
GBGB9525657.4A GB9525657D0 (en)	1995-12-15	1995-12-15	Vaccines
GBGB9606032.2A GB9606032D0 (en)	1996-03-22	1996-03-22	Vaccines
PCT/EP1996/002690 WO1997000697A1 (en)	1995-06-23	1996-06-19	A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate

Publications (1)

Publication Number	Publication Date
SK176197A3 true SK176197A3 (en)	1998-07-08

Family

ID=27451299

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1761-97A SK176197A3 (en)	1995-06-23	1996-06-19	A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate

Country Status (35)

Country	Link
EP (2)	EP1082965B1 (da)
JP (2)	JP4850987B2 (da)
KR (1)	KR100425929B1 (da)
CN (1)	CN1146444C (da)
AP (1)	AP812A (da)
AR (1)	AR003006A1 (da)
AT (2)	ATE199831T1 (da)
AU (1)	AU696338B2 (da)
BG (1)	BG62720B1 (da)
BR (1)	BRPI9609414B8 (da)
CA (1)	CA2222455C (da)
CY (1)	CY2297B1 (da)
CZ (1)	CZ288908B6 (da)
DE (2)	DE69637950D1 (da)
DK (2)	DK1082965T3 (da)
DZ (1)	DZ2055A1 (da)
EA (1)	EA199700413A1 (da)
EG (1)	EG25924A (da)
ES (2)	ES2325301T3 (da)
GR (1)	GR3036088T3 (da)
HU (1)	HU224514B1 (da)
IL (1)	IL122588A (da)
MA (1)	MA23918A1 (da)
MY (1)	MY114786A (da)
NO (1)	NO325169B1 (da)
NZ (1)	NZ312132A (da)
OA (1)	OA10646A (da)
PE (1)	PE11298A1 (da)
PL (1)	PL184872B1 (da)
PT (2)	PT1082965E (da)
SI (2)	SI1082965T1 (da)
SK (1)	SK176197A3 (da)
TR (1)	TR199701682T1 (da)
TW (1)	TW467746B (da)
WO (1)	WO1997000697A1 (da)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG48365A1 (en)	1992-05-23	1998-04-17	Smithkline Beecham Biolog	Combined vaccines comprising hepatitis b surface antigen and other antigens
US6355450B1 (en)	1995-04-21	2002-03-12	Human Genome Sciences, Inc.	Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof
US6468765B1 (en)	1995-04-21	2002-10-22	Human Genome Sciences, Inc.	Selected Haemophilus influenzae Rd polynucleotides and polypeptides
US6696065B1 (en)	1995-05-04	2004-02-24	Aventis Pastuer Limited	Acellular pertussis vaccines and methods of preparation thereof
PL184872B1 (pl) *	1995-06-23	2003-01-31	Smithkline Beecham Biolog	Kombinowana szczepionkaĆ zestaw do przygotowania kombinowanej szczepionkiĆ sposób wytwarzania kombinowanej szczepionki i jej zastosowanie
DE69736709T2 (de) *	1996-07-02	2007-10-04	Sanofi Pasteur Ltd., Toronto	Vielwertige dtp-polio-impfstoffe
GB9806456D0 (en) *	1998-03-25	1998-05-27	Smithkline Beecham Biolog	Vaccine composition
KR100629028B1 (ko)	1998-10-16	2006-09-26	글락소스미스클라인 바이오로지칼즈 에스.에이.	애쥬번트 시스템 및 백신
US6585973B1 (en)	1998-10-29	2003-07-01	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Method for preparing solid phase conjugated vaccine
GB9928196D0 (en)	1999-11-29	2000-01-26	Chiron Spa	Combinations of B, C and other antigens
GB0108364D0 (en) *	2001-04-03	2001-05-23	Glaxosmithkline Biolog Sa	Vaccine composition
CZ20024224A3 (cs) *	2000-06-29	2003-05-14	Glaxosmithkline Biologicals S. A.	Farmaceutický prostředek
SI21352A (sl)	2001-01-23	2004-06-30	Aventis Pasteur	Multivalentno meningokokno cepivo iz konjugata polisaharida-proteina
GB0115176D0 (en)	2001-06-20	2001-08-15	Chiron Spa	Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en)	2001-07-26	2001-09-19	Chiron Spa	Histidine vaccines
HUE031886T2 (en)	2002-10-11	2017-08-28	Glaxosmithkline Biologicals Sa	Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
CA2503946C (en)	2002-11-01	2016-08-16	Glaxosmithkline Biologicals S.A.	Drying process
GB0227346D0 (en)	2002-11-22	2002-12-31	Chiron Spa	741
EP2172213B1 (en)	2003-01-30	2013-04-03	Novartis AG	Injectable vaccines against multiple meningococcal serogroups
GB0313916D0 (en)	2003-06-16	2003-07-23	Glaxosmithkline Biolog Sa	Vaccine composition
EP1667712B1 (en) *	2003-10-02	2010-07-21	GlaxoSmithKline Biologicals S.A.	B. pertussis antigens and use thereof in vaccination
GB0323103D0 (en)	2003-10-02	2003-11-05	Chiron Srl	De-acetylated saccharides
NZ546430A (en)	2003-10-02	2009-04-30	Novartis Vaccines & Diagnostic	Liquid vaccines for multiple meningococcal serogroups
GB0405787D0 (en) *	2004-03-15	2004-04-21	Chiron Srl	Low dose vaccines
NZ550533A (en)	2004-04-30	2010-02-26	Novartis Vaccines & Diagnostic	Meningococcal conjugate vaccination comprising N. meningitidis and diphtheria toxin
GB0409745D0 (en)	2004-04-30	2004-06-09	Chiron Srl	Compositions including unconjugated carrier proteins
GB0500787D0 (en)	2005-01-14	2005-02-23	Chiron Srl	Integration of meningococcal conjugate vaccination
GB0505518D0 (en)	2005-03-17	2005-04-27	Chiron Srl	Combination vaccines with whole cell pertussis antigen
GB0505996D0 (en)	2005-03-23	2005-04-27	Glaxosmithkline Biolog Sa	Fermentation process
CA2605179A1 (en)	2005-04-18	2006-10-26	Novartis Vaccines And Diagnostics, Inc.	Expressing hepatitis b virus surface antigen for vaccine preparation
PE20110072A1 (es)	2005-06-27	2011-02-04	Glaxosmithkline Biolog Sa	Composicion inmunogenica
GB0522765D0 (en)	2005-11-08	2005-12-14	Chiron Srl	Combination vaccine manufacture
GB0524066D0 (en)	2005-11-25	2006-01-04	Chiron Srl	741 ii
US10828361B2 (en)	2006-03-22	2020-11-10	Glaxosmithkline Biologicals Sa	Regimens for immunisation with meningococcal conjugates
PL2004225T3 (pl)	2006-03-22	2012-09-28	Novartis Ag	Schematy immunizacji koniugatami meningokokowymi
JP5814507B2 (ja)	2006-09-07	2015-11-17	グラクソスミスクラインバイオロジカルズソシエテアノニム	ワクチン
JP2010525035A (ja)	2007-05-02	2010-07-22	グラクソスミスクラインバイオロジカルズソシエテアノニム	ワクチン
ES2555786T3 (es)	2007-06-04	2016-01-08	Glaxosmithkline Biologicals Sa	Formulación de vacunas contra la meningitis
FR2918671B1 (fr)	2007-07-10	2010-10-15	Sanofi Pasteur	Milieu de culture d'haemophilus influenzae type b.
GB0818453D0 (en)	2008-10-08	2008-11-12	Novartis Ag	Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
GB0822633D0 (en)	2008-12-11	2009-01-21	Novartis Ag	Formulation
TW201043267A (en) *	2009-03-19	2010-12-16	Intervet Int Bv	In situ constituting a vaccine for administration to a predetermined herd of animals
EP2411048B1 (en) *	2009-03-24	2020-05-06	GlaxoSmithKline Biologicals SA	Adjuvanting meningococcal factor h binding protein
IT1398927B1 (it)	2009-06-25	2013-03-28	Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi	Espressione batterica di un gene artificiale per la produzione di crm197 e derivati.
GB0917647D0 (en)	2009-10-08	2009-11-25	Glaxosmithkline Biolog Sa	Expression system
EP2661277A2 (en)	2011-01-05	2013-11-13	Bharat Biotech International Limited	A combination heptavalent vaccine
GB201105981D0 (en)	2011-04-08	2011-05-18	Glaxosmithkline Biolog Sa	Novel process
TW201302779A (zh)	2011-04-13	2013-01-16	Glaxosmithkline Biolog Sa	融合蛋白質及組合疫苗
EP2592137A1 (en)	2011-11-11	2013-05-15	Novartis AG	Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
GB2495341B (en)	2011-11-11	2013-09-18	Novartis Ag	Fermentation methods and their products
DE102011118371B4 (de)	2011-11-11	2014-02-13	Novartis Ag	Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
DE102011122891B4 (de)	2011-11-11	2014-12-24	Novartis Ag	Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
BR112014017898B1 (pt)	2012-02-01	2021-10-13	Glaxosmithkline Biologicals S.A.	Processo de fermentação
CN104487086B (zh) *	2012-07-07	2019-08-30	巴拉特生物技术国际有限公司	无动物源的不含酒精的疫苗组合物及其制备方法
US20140037680A1 (en)	2012-08-06	2014-02-06	Glaxosmithkline Biologicals, S.A.	Novel method
AU2013301312A1 (en)	2012-08-06	2015-03-19	Glaxosmithkline Biologicals S.A.	Method for eliciting in infants an immune response against RSV and B. pertussis
EP2906239A1 (en)	2012-10-12	2015-08-19	GlaxoSmithKline Biologicals SA	Non-cross-linked acellular pertussis antigens for use in combination vaccines
MX2016001695A (es)	2013-08-05	2016-05-02	Glaxosmithkline Biolog Sa	Composiciones inmunogenas de combinacion.
US11219680B2 (en)	2017-02-24	2022-01-11	Merck Sharp & Dohme Corp.	Polysaccharide-protein conjugates utilizing diphtheria toxin fragment B as a carrier
CN111032078A (zh)	2017-07-18	2020-04-17	血清研究所印度私人有限公司	具有改善的稳定性、增强的免疫原性和降低的反应原性的免疫原性组合物及其制备方法
EA202190778A1 (ru)	2018-10-12	2021-08-05	Серум Инститьют Оф Индия Прайват Лтд	Композиция комбинированной вакцины, содержащая уменьшенную дозу инактивированного полиовируса, и способ её получения
WO2020236973A1 (en)	2019-05-20	2020-11-26	Soligenix, Inc.	Compositions and methods of manufacturing trivalent filovirus vaccines
CN111658617A (zh) *	2019-10-14	2020-09-15	四川大学	一种含铝佐剂疫苗的冻干制剂及其制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4235877A (en)	1979-06-27	1980-11-25	Merck & Co., Inc.	Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en)	1979-11-13	1983-02-08	Likhite Vilas V	Antigen compounds
IL61904A (en)	1981-01-13	1985-07-31	Yeda Res & Dev	Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4695624A (en)	1984-05-10	1987-09-22	Merck & Co., Inc.	Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
ATE128628T1 (de) *	1990-08-13	1995-10-15	American Cyanamid Co	Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff.
US5153312A (en)	1990-09-28	1992-10-06	American Cyanamid Company	Oligosaccharide conjugate vaccines
ES2204900T3 (es)	1992-02-11	2004-05-01	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Estructura inmuinogena de doble vector.
SG48365A1 (en)	1992-05-23	1998-04-17	Smithkline Beecham Biolog	Combined vaccines comprising hepatitis b surface antigen and other antigens
DE69323264D1 (de) *	1992-10-27	1999-03-11	American Cyanamid Co	Pädiatrische Kombinationsvakzine mit verbesserter Immunogenizität jeder Vakzine komponente
PL184872B1 (pl) *	1995-06-23	2003-01-31	Smithkline Beecham Biolog	Kombinowana szczepionkaĆ zestaw do przygotowania kombinowanej szczepionkiĆ sposób wytwarzania kombinowanej szczepionki i jej zastosowanie

1996
- 1996-06-19 PL PL96324242A patent/PL184872B1/pl unknown
- 1996-06-19 IL IL12258896A patent/IL122588A/en not_active IP Right Cessation
- 1996-06-19 SI SI9630768T patent/SI1082965T1/sl unknown
- 1996-06-19 EA EA199700413A patent/EA199700413A1/ru unknown
- 1996-06-19 HU HU9900061A patent/HU224514B1/hu active IP Right Grant
- 1996-06-19 EP EP00203874A patent/EP1082965B1/en not_active Expired - Lifetime
- 1996-06-19 TR TR97/01682T patent/TR199701682T1/xx unknown
- 1996-06-19 PT PT00203874T patent/PT1082965E/pt unknown
- 1996-06-19 JP JP50358197A patent/JP4850987B2/ja not_active Expired - Lifetime
- 1996-06-19 ES ES00203874T patent/ES2325301T3/es not_active Expired - Lifetime
- 1996-06-19 SK SK1761-97A patent/SK176197A3/sk unknown
- 1996-06-19 CZ CZ19974189A patent/CZ288908B6/cs not_active IP Right Cessation
- 1996-06-19 BR BRPI9609414A patent/BRPI9609414B8/pt not_active IP Right Cessation
- 1996-06-19 AT AT96922871T patent/ATE199831T1/de active
- 1996-06-19 WO PCT/EP1996/002690 patent/WO1997000697A1/en not_active Ceased
- 1996-06-19 CA CA2222455A patent/CA2222455C/en not_active Expired - Lifetime
- 1996-06-19 KR KR1019970709651A patent/KR100425929B1/ko not_active Expired - Lifetime
- 1996-06-19 DE DE69637950T patent/DE69637950D1/de not_active Expired - Lifetime
- 1996-06-19 PT PT96922871T patent/PT833662E/pt unknown
- 1996-06-19 AP APAP/P/1997/001159A patent/AP812A/en active
- 1996-06-19 AT AT00203874T patent/ATE433329T1/de active
- 1996-06-19 CN CNB961949732A patent/CN1146444C/zh not_active Expired - Lifetime
- 1996-06-19 DK DK00203874T patent/DK1082965T3/da active
- 1996-06-19 DK DK96922871.7T patent/DK0833662T4/da active
- 1996-06-19 EP EP96922871A patent/EP0833662B2/en not_active Expired - Lifetime
- 1996-06-19 NZ NZ312132A patent/NZ312132A/en not_active IP Right Cessation
- 1996-06-19 DE DE69612198T patent/DE69612198T3/de not_active Expired - Lifetime
- 1996-06-19 AU AU63591/96A patent/AU696338B2/en not_active Expired
- 1996-06-19 ES ES96922871T patent/ES2157447T5/es not_active Expired - Lifetime
- 1996-06-19 SI SI9630310T patent/SI0833662T2/sl unknown
- 1996-06-21 MA MA24292A patent/MA23918A1/fr unknown
- 1996-06-21 MY MYPI96002531A patent/MY114786A/en unknown
- 1996-06-21 PE PE1996000474A patent/PE11298A1/es not_active IP Right Cessation
- 1996-06-21 AR ARP960103253A patent/AR003006A1/es active IP Right Grant
- 1996-06-22 EG EG57496A patent/EG25924A/xx active
- 1996-06-22 DZ DZ960099A patent/DZ2055A1/fr active
- 1996-06-25 TW TW085107646A patent/TW467746B/zh not_active IP Right Cessation
1997
- 1997-12-19 OA OA70169A patent/OA10646A/en unknown
- 1997-12-22 NO NO19976035A patent/NO325169B1/no not_active IP Right Cessation
- 1997-12-23 BG BG102146A patent/BG62720B1/bg unknown
2001
- 2001-06-19 GR GR20010400933T patent/GR3036088T3/el unknown
2002
- 2002-09-23 CY CY0200056A patent/CY2297B1/xx unknown
2008
- 2008-02-14 JP JP2008033301A patent/JP2008120833A/ja active Pending

Also Published As

Publication number	Publication date
WO1997000697A1 (en)	1997-01-09
DE69612198T2 (de)	2001-11-08
HK1009764A1 (en)	1999-06-11
IL122588A0 (en)	1998-06-15
CY2297B1 (en)	2003-07-04
NO325169B1 (no)	2008-02-11
NZ312132A (en)	1999-04-29
EP0833662B2 (en)	2011-01-26
MX9710521A (es)	1998-08-30
AU696338B2 (en)	1998-09-10
DK0833662T4 (da)	2011-02-28
EP1082965A1 (en)	2001-03-14
SI0833662T1 (en)	2001-12-31
KR19990028336A (ko)	1999-04-15
MA23918A1 (fr)	1996-12-31
MY114786A (en)	2003-01-31
DK1082965T3 (da)	2009-07-27
HK1037516A1 (en)	2002-02-15
EG25924A (en)	2012-10-22
ES2325301T3 (es)	2009-09-01
PE11298A1 (es)	1998-03-20
BG62720B1 (bg)	2000-06-30
CA2222455A1 (en)	1997-01-09
EP1082965B1 (en)	2009-06-10
DE69612198D1 (de)	2001-04-26
DZ2055A1 (fr)	2002-10-20
GR3036088T3 (en)	2001-09-28
BRPI9609414B8 (pt)	2021-05-25
PL184872B1 (pl)	2003-01-31
HUP9900061A1 (hu)	1999-04-28
EP0833662A1 (en)	1998-04-08
DK0833662T3 (da)	2001-07-09
ES2157447T5 (es)	2011-04-29
ATE199831T1 (de)	2001-04-15
ATE433329T1 (de)	2009-06-15
ES2157447T3 (es)	2001-08-16
KR100425929B1 (ko)	2004-05-31
BR9609414A (pt)	1999-05-18
PT833662E (pt)	2001-09-28
CN1146444C (zh)	2004-04-21
SI1082965T1 (sl)	2009-08-31
JPH11507935A (ja)	1999-07-13
CN1188418A (zh)	1998-07-22
DE69612198T3 (de)	2011-08-18
JP2008120833A (ja)	2008-05-29
OA10646A (en)	2002-09-18
BG102146A (en)	1998-10-30
NO976035L (no)	1998-02-16
EP0833662B1 (en)	2001-03-21
IL122588A (en)	2001-12-23
CA2222455C (en)	2013-05-28
NO976035D0 (no)	1997-12-22
TR199701682T1 (xx)	1998-06-22
CZ418997A3 (cs)	1998-06-17
AP9701159A0 (en)	1998-01-31
AP812A (en)	2000-02-24
HUP9900061A3 (en)	2000-03-28
SI0833662T2 (sl)	2011-06-30
AU6359196A (en)	1997-01-22
PL324242A1 (en)	1998-05-11
CZ288908B6 (cs)	2001-09-12
DE69637950D1 (de)	2009-07-23
PT1082965E (pt)	2009-07-01
JP4850987B2 (ja)	2012-01-11
HU224514B1 (hu)	2005-10-28
AR003006A1 (es)	1998-05-27
BR9609414B1 (pt)	2013-11-19
TW467746B (en)	2001-12-11
EA199700413A1 (ru)	1998-08-27

Publication	Publication Date	Title
CA2222455C (en)	2013-05-28	A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
JP4233113B2 (ja)	2009-03-04	多糖類抗原−キャリア蛋白接合体および遊離キャリア蛋白を有してなるワクチン
AU3417299A (en)	1999-10-18	Vaccine composition
US6756040B2 (en)	2004-06-29	Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminum phosphate
US20030022304A1 (en)	2003-01-30	Vaccine composition
MXPA97010521A (en)	1998-11-12	A composition of vaccines including an antigen conjugated of polysaccharid adsorbided in alumi phosphate
HK1009764B (en)	2002-02-08	A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
HK1037516B (en)	2010-01-22	A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate